.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,496,820

« Back to Dashboard

Details for Patent: 5,496,820

Title: Ophthalmic use of S-timolol hemihydrate
Abstract:A novel composition and method for making compositions containing S-timolol hemihydrate having the formula: ##STR1## wherein the compositions are useful as pharmaceutical agents for topical administration to an eye for treating glaucoma and/or lowering intraocular pressure.
Inventor(s): Peralampi; Markku (SF-36200 Kangasala, FI)
Assignee:
Filing Date:Jul 27, 1993
Application Number:08/097,880
Claims:1. An Ophthalmic topical composition containing a therapeutically effective amount of (S)-(-)-3-morpholino-4-( 3-tert-butyl-amino-2 hydroxypropoxy)-1, 2,5-thiadiazole hemihydrate together with an ophthalmic carrier.

2. Ophthalmic composition according to claim 1 which is in the form of solution.

3. Ophthalmic composition according to claim 1 wherein the ophthalmic carrier is water.

4. Ophthalmic composition according to claim 2 which is a unit dose form.

5. Ophthalmic composition according to claim 4 wherein the ophthalmic carrier is water.

6. Ophthalmic composition according to claim 1 which is in the form of a gel.

7. Ophthalmic composition according to claim 1 which is in the form of an oil.

8. Ophthalmic composition according to claim 1 which is in the form of an ointment.

9. Ophthalmic composition according to claim 1 which is in the form of an insert.

10. Ophthalmic composition according to claim 1 which contains 0.01 to 5% by weight of (S)-(-)-3-morpholino-4-(3-tert-butyl-amino-2 hydroxypropoxy)-1,2,5-thiadiazole hemihydrate.

11. Ophthalmic composition according to claim 10 contains 0.1 to 2% by weight of (S)-(-)-3-morpholino-4-( 3-tert-butyl-amino-2 hydroxypropoxy)-1,2,5-thiadiazole hemihydrate.

12. Ophthalmic composition according to claim 1 in unit dose form consisting of (S)-(-)-3-morpholino-4-(3-tert-butyl-amino-2 hydroxypropoxy)-1,2,5-thiadiazole hemihydrate, a water carrier and buffer.

13. Ophthalmic composition according to claim 12 containing 0.001 mg to 5 mg of (S)-(-)-3-morpholino-4-(3-tert-butyl-amino-2 hydroxypropoxy)-1,2,5-thiadiazole hemihydrate.

14. Method for the topical treatment of glaucoma and ocular hypertension which comprises administering to the eye of a human or animal in need of such treatment a therapeutically effective amount of (S)-(-)-3-morpholino-4-(3-tert-butyl-amino-2 hydroxypropoxy)-1,2,5-thiadiazole hemihydrate.

15. Method according to claim 14 wherein (S)-(-)-3-morpholino-4-(3-tert-butyl-amino-2 hydroxypropoxy)-1,2,5-thiadiazole hemihydrate is administered in the form of an ophthalmic composition at a concentration of 0.01 to 5% by weight in an ophthalmic carrier.

16. Process for the pharmaceutically treating a subject with (S)-(-)-3-morpholino-4-(3-tert-butyl-amino-2 hydroxypropoxy)-1,2,5-thiadiazole hemihydrate comprising the steps of:

preparing a composition containing an intraocular pressure effective lowering amount of (S)-(-)-3-morpholino-4-(3-tert-butyl-amino-2 hydroxypropoxy)-1,2,5-thiadiazole hemihydrate; and

topically applying the prepared composition to the eye of the subject.

17. Process of claim 16 wherein the step of preparing comprises admixing one or more selected adjuvants pharmaceutically acceptable for topical administration to the eye together with the (S)-(-)-3-morpholino-4-(3-tert-butyl-amino-2 hydroxypropoxy)-1,2,5-thiadiazole hemihydrate.

18. Process of claim 17 wherein the composition is formed into a dosage form.

19. A pharmaceutical composition for topical ophthalmic application to the eye of a subject containing an intraocular pressure lowering effective amount of (S)-(-)-3-morpholino-4-(3-tert-butyl-amino-2-hydroxypropox)-1,2,5-thiadiaz ole hemihydrate wherein the composition is in a dosage form.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc